Clinical Trials Browser

Terminated × Afatinib × Clear all

NCT05588609 2026-04-27

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Phase 2 Terminated

GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

Phase 2 Terminated

32 enrolled 14 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00748709 2025-02-11

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Phase 2 Terminated

20 enrolled 11 charts

Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02768337 2024-01-31

CamBMT1

Phase 1/2 Terminated

BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Lung Neoplasms

NCT01824823 2023-06-28

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

Phase 2 Terminated

3 enrolled 6 charts

Squamous Cell Carcinoma of Head and Neck

NCT01320280 2022-07-01

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Phase 2 Terminated

Neoplasms, Prostatic Neoplasms

NCT03711422 2022-06-14

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Meningeal Neoplasms

NCT03054038 2022-04-14

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02115048 2019-12-26

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Phase 2 Terminated

44 enrolled 15 charts

Breast Neoplasms

NCT01679405 2019-09-06

BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer

Phase 1 Terminated

9 enrolled 12 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT02271906 2019-04-30

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Phase 2 Terminated

2 enrolled 8 charts

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT02595840 2019-04-19

Trans-MARBLE

Phase 2 Terminated

Non-small-cell Lung Cancer With Somatic EGFR Mutations

NCT02131155 2019-03-01

LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Phase 3 Terminated

36 enrolled 6 charts

Head and Neck Neoplasms

NCT01732640 2018-07-26

A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

Phase 1/2 Terminated

9 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck

NCT02488694 2018-01-09

MARBLE

Phase 2 Terminated

Non-small-cell Lung Cancer With Somatic EGFR Mutations

NCT01345669 2017-12-07

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Phase 3 Terminated

617 enrolled 13 charts

Head and Neck Neoplasms

NCT02695290 2017-09-18

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

Phase 4 Terminated

1 enrolled 3 charts

Carcinoma, Non-Small-Cell Lung

NCT01531764 2013-10-18

BIBW 2992 (Afatinib) and Vinorelbine

Phase 2 Terminated

Breast Neoplasms